A randomized, placebo-controlled Phase 2 trial (NCT02453711) of once-daily subcutaneous semaglutide (0.05, 0.1, 0.2, 0.3, or 0.4 mg following 4-weekly escalations) in subjects with obesity without T2D, showed mean weight losses of -6.0% (0.05 mg) to -13.8% (0.4 mg) with semaglutide vs -2.3% with placebo at week 52
Three-stage reconstruction of the airway and alimentary tract in a case of tracheal agenesis
Metabolic effects of a carnitine-free diet fed to college students
Elafibranor (GFT505) Elafibranor is an unlicensed dual agonist of PPAR/ receptors, and has been shown to improve steatosis, inflammation, and fibrosis in mouse models of NAFLD [30]
Liraglutide is an injectable drug taken once a day, while semaglutide is an injectable drug taken once a week or an oral drug taken daily